【摘要】 目的:分析卵巢癌组织中KI67蛋白的表达及其与患者临床病理特征及预后的关系。方法:收集172例卵巢癌患者(卵巢浆液性癌153例、黏液性癌3例、透明细胞癌2例、子宫内膜样腺癌13例、鳞状细胞癌1例)的卵巢癌组织石蜡标本,另同期收集8例卵巢良性肿瘤患者的卵巢肿瘤组织标本及10份正常卵巢组织标本作为对照。采用免疫组化方法检测KI67的表达情况,并分析其与卵巢癌患者临床病理特征及预后的关系。结果:KI67蛋白在卵巢癌组织中的阳性表达率为97.09%(167/172),明显高于正常卵巢组织及良性卵巢肿瘤组织(P<0.05)。KI67的表达与卵巢癌患者的年龄、是否浆液性卵巢癌、细胞分化程度、病理分期、是否淋巴结转移、无进展生存时间(PFS)及总生存时间(OS)均无明显相关关系(均P>0.05)。结论:卵巢癌患者KI67蛋白表达明显上调,KI67表达水平与卵巢癌患者的生存预后并无明显相关关系。更多还原

【Abstract】 Objective: To investigate the expression of KI67 protein in patients with epithelial ovarian cancer and its clinical significance. Methods: Ovarian specimens were obtained from surgeries performed between 2005 and 2013. The patients were divided into three groups: group A,epithelial ovarian cancer(n=172);group B,benign epithelial neoplasia(n=8);and group C,normal ovaries(n=10). The protein expression of KI67 was measured by immunohistochemistry methods. The correlation between the KI67 expression and clinical pathological characteristics was analyzed. Results: The positive expression rate of KI67 protein was significantly higher in group A(97. 09%)compared to group B and C(P<0. 05). There was no correlation between the expression of KI67 and age,serous ovarian cancer,cell differentiation,pathological stage,lymph node metastasis,progression-free survival(PFS)time and overall survival(OS)time of ovarian cancer patients(P>0. 05).Conclusion: KI67 protein expression was up-regulated in ovarian cancer patients and was not associated with survival prognosis of patients.更多还原